Equities

Windlas Biotech Ltd

WINDLAS:NSI

Windlas Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)664.00
  • Today's Change-0.600 / -0.09%
  • Shares traded71.92k
  • 1 Year change+138.33%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024 11:17 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Windlas Biotech Limited is an India-based company that is primarily engaged in the manufacturing and trading of pharmaceutical products. The Company provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. It has capabilities for both solid and liquid pharmaceutical dosage forms. The Company markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. It also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.

  • Revenue in INR (TTM)6.31bn
  • Net income in INR581.87m
  • Incorporated2001
  • Employees1.05k
  • Location
    Windlas Biotech Ltd40/1 Mohabewala Industrial AreaDEHARADUN 248110IndiaIND
  • Websitehttps://windlas.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jagsonpal Pharmaceuticals Ltd2.09bn224.63m7.94bn940.0035.474.2432.923.818.478.4778.3170.881.015.2713.12--10.9010.9512.3013.2955.0058.1710.769.219.6326.290.045543.81-11.834.58-15.9425.50-35.6982.06
Vimta Labs Ltd3.18bn410.09m9.81bn1.37k24.263.0713.043.0818.2418.24141.64144.200.83493.233.81--10.7610.5312.6012.7776.0273.6512.8912.162.4624.790.056611.150.02238.40-14.8710.1335.880.00
Remus Pharmaceuticals Ltd450.27m85.03m9.96bn38.00105.7838.34110.9022.1263.9263.92361.02176.36------11,849,290.00--------52.39--18.88--1.35--0.2933--82.17--151.14------
Kopran Ltd6.15bn509.56m10.08bn394.0019.922.0515.791.6410.5010.50126.95101.900.88242.993.28--7.328.4710.2212.2334.6034.188.298.891.4443.230.16825.4111.5411.4287.1116.2312.53--
Bliss GVS Pharma Ltd7.70bn754.54m10.23bn763.0013.791.069.471.337.087.0872.8692.390.64983.451.95--6.886.468.378.2250.3944.2110.599.924.3417.970.09057.932.48-3.036.49-9.42-8.33-12.94
Lincoln Pharmaceuticals Ltd5.81bn933.05m10.76bn1.70k11.531.8210.351.8546.5846.58289.81295.980.90173.783.90--14.4913.9516.6116.5452.0651.2116.0714.714.0160.950.0018--13.769.6627.9913.8821.543.71
Syncom Formulations (India) Ltd2.63bn253.14m10.76bn799.0033.683.7435.834.090.340.343.563.070.67327.422.95--6.477.509.0010.2340.4434.599.619.382.385.570.201--17.457.1226.1317.95----
Beta Drugs Ltd2.56bn347.57m11.44bn315.0032.928.0625.004.4736.1536.15266.28147.681.244.443.728,126,721.0016.85--25.36--41.88--13.58--1.4318.210.098--23.54--23.73------
Zota Health Care Ltd1.80bn-143.48m11.94bn338.00--12.93207.916.62-5.59-5.5970.4034.810.93412.026.55---7.42-1.38-10.54-1.8546.4336.48-7.95-1.330.7851-2.620.5143--28.9616.08-148.54--39.850.00
Windlas Biotech Ltd6.31bn581.87m12.46bn1.05k21.442.7717.401.9727.9427.94302.99216.331.095.794.99--10.07--13.50--37.21--9.22--2.1558.580.008--22.97--36.51------
Ngl Fine Chem Ltd3.39bn413.43m13.66bn343.0033.045.2025.794.0366.9266.92548.61425.111.054.514.36--12.8715.0616.6119.5853.1846.7912.2013.151.9630.640.12183.0621.7917.20101.5815.4714.490.00
Hester Biosciences Ltd3.05bn188.89m14.14bn693.0066.774.8536.884.6424.8924.89392.38343.010.45721.203.85--3.186.154.007.6968.5268.836.9512.831.311.840.446623.2714.4511.33-29.06-14.591.49-11.42
SMS Pharmaceuticals Ltd7.09bn498.26m15.49bn1.10k31.072.8919.192.185.895.8983.8463.360.74132.183.69--5.145.437.417.3329.8332.676.947.870.9053.630.34366.5935.868.81805.824.478.419.86
Data as of Jun 07 2024. Currency figures normalised to Windlas Biotech Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

10.47%Per cent of shares held by top holders
HolderShares% Held
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 20231.95m9.40%
UTI Asset Management Co. Ltd. (Investment Management)as of 30 Apr 2024201.84k0.97%
Macquarie Funds Management Hong Kong Ltd.as of 30 Nov 202120.45k0.10%
American Century Investment Management, Inc.as of 09 May 2024461.000.00%
More ▼
Data from 29 Feb 2024 - 15 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.